Mechanistic enhancement of the intestinal absorption of drugs containing the polar guanidino functionality

Bibliography

• Mori A. Biochemistry and neurotoxicology of guanidino compounds. History and recent advances. Pavlov J Biol Sci 1987;22(3):85-94
   PubMedGoogle Scholar
• Hiramatsu M. A role for guanidino compounds in the brain. Mol Cell Biochem 2003;244(1-2):57-62
   PubMed Web of Science ®Google Scholar
• Taes YE, Marescau B, De Vriese A, Guanidino compounds after creatine supplementation in renal failure patients and their relation to inflammatory status. Nephrol Dial Transplant 2008;23(4):1330-5
   PubMed Web of Science ®Google Scholar
• De Deyn PP, Vanholder R, Eloot S, Guanidino compounds as uremic (neuro)toxins. Semin Dial 2009;22(4):340-5
   PubMed Web of Science ®Google Scholar
• Greenhill JV, Lue P. Amidines and guanidines in medicinal chemistry. Prog Med Chem 1993;30:203-326
   PubMedGoogle Scholar
• Berlinck RG, Burtoloso AC, Kossuga MH. The chemistry and biology of organic guanidine derivatives. Nat Prod Rep 2008;25(5):919-54
   PubMed Web of Science ®Google Scholar
• Morris Jr SM. Enzymes of arginine metabolism. J Nutr 2004;134(Suppl 10):2743S-2747S; discussion 65S-67S
   Google Scholar
• Masic LP. Arginine mimetic structures in biologically active antagonists and inhibitors. Curr Med Chem 2006;13(30):3627-48
   PubMed Web of Science ®Google Scholar
• Closs EI, Simon A, Vekony N, Plasma membrane transporters for arginine. J Nutr 2004;134(Suppl 10):2752S-2759S, disscussion 2765S-2767S
   Google Scholar
• Broer S. Amino acid transport across mammalian intestinal and renal epithelia. Physiol Rev 2008;88(1):249-86
   PubMed Web of Science ®Google Scholar
• Kiechel JR. Pharmacokinetics and metabolism of guanfacine in man: a review. Br J Clin Pharmacol 1980;10(Suppl 1):25S-32S
   Google Scholar
• Palm K, Luthman K, Ros J, Effect of molecular charge on intestinal epithelial drug transport: pH-dependent transport of cationic drugs. J Pharmacol Exp Ther 1999;291(2):435-43
   PubMed Web of Science ®Google Scholar
• Islam MS, Narurkar MM. Solubility, stability and ionization behaviour of famotidine. J Pharm Pharmacol 1993;45(8):682-6
   PubMed Web of Science ®Google Scholar
• Dahan A, Miller JM, Hilfinger JM, High-permeability criterion for BCS classification: segmental/pH dependent permeability considerations. Mol Pharm 2010;7(5):1827-34
   PubMedGoogle Scholar
• Zhou SY, Piyapolrungroj N, Pao L, Regulation of paracellular absorption of cimetidine and 5-aminosalicylate in rat intestine. Pharm Res 1999;16(11):1781-5
   PubMed Web of Science ®Google Scholar
• Mahato RI, Narang AS, Thoma L, Emerging trends in oral delivery of peptide and protein drugs. Crit Rev Ther Drug Carrier Syst 2003;20(2-3):153-214
   PubMed Web of Science ®Google Scholar
• Hamman JH, Enslin GM, Kotze AF. Oral delivery of peptide drugs: barriers and developments. BioDrugs 2005;19(3):165-77
   PubMed Web of Science ®Google Scholar
• Chremos AN. Clinical pharmacology of famotidine: a summary. J Clin Gastroenterol 1987;9(Suppl 2):7-12
   PubMedGoogle Scholar
• Lee K, Thakker DR. Saturable transport of H2-antagonists ranitidine and famotidine across Caco-2 cell monolayers. J Pharm Sci 1999;88(7):680-7
   PubMed Web of Science ®Google Scholar
• Bourdet DL, Pritchard JB, Thakker DR. Differential substrate and inhibitory activities of ranitidine and famotidine toward human organic cation transporter 1 (hOCT1; SLC22A1), hOCT2 (SLC22A2), and hOCT3 (SLC22A3). J Pharmacol Exp Ther 2005;315(3):1288-97
   PubMed Web of Science ®Google Scholar
• Lee K, Ng C, Brouwer KL, Secretory transport of ranitidine and famotidine across Caco-2 cell monolayers. J Pharmacol Exp Ther 2002;303(2):574-80
   PubMed Web of Science ®Google Scholar
• Dahan A, Amidon GL. Segmental dependent transport of low permeability compounds along the small intestine due to P-glycoprotein: the role of efflux transport in the oral absorption of BCS class III drugs. Mol Pharm 2009;6(1):19-28
   PubMedGoogle Scholar
• Dahan A, Sabit H, Amidon GL. Multiple efflux pumps are involved in the transepithelial transport of colchicine: combined effect of P-gp and MRP2 leads to decreased intestinal absorption throughout the entire small intestine. Drug Metab Dispos 2009;37(10):2028-36
   PubMed Web of Science ®Google Scholar
• Dahan A, Amidon G. Grapefruit juice and its constituents augment colchicine intestinal absorption: potential hazardous interaction and the role of P-glycoprotein. Pharm Res 2009;26(4):883-92
   PubMed Web of Science ®Google Scholar
• Dahan A, Amidon GL. Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting. Am J Physiol Gastrointest Liver Physiol 2009;297(2):G371-7
   Google Scholar
• Dahan A, Amidon GL. MRP2 mediated drug–drug interaction: indomethacin increases sulfasalazine absorption in the small intestine, potentially decreasing its colonic targeting. Int J Pharm 2010;386(1-2):216-20
   PubMedGoogle Scholar
• Dahan A, Sabit H, Amidon G. The H2 receptor antagonist nizatidine is a P-glycoprotein substrate: characterization of its intestinal epithelial cell efflux transport. AAPS J 2009;11(2):205-13
   PubMed Web of Science ®Google Scholar
• Dahan A, West BT, Amidon GL. Segmental-dependent membrane permeability along the intestine following oral drug administration: evaluation of a triple single-pass intestinal perfusion (TSPIP) approach in the rat. Eur J Pharm Sci 2009;36(2-3):320-9
   PubMed Web of Science ®Google Scholar
• Pentikainen PJ, Neuvonen PJ, Penttila A. Pharmacokinetics of metformin after intravenous and oral administration to man. Eur J Clin Pharmacol 1979;16(3):195-202
   PubMed Web of Science ®Google Scholar
• Nicklin P, Keates AC, Page T, Transfer of metformin across monolayers of human intestinal Caco-2 cells and across rat intestine. Int J Pharm 1996;128(1-2):155-62
   Google Scholar
• Kimura N, Masuda S, Tanihara Y, Metformin is a superior substrate for renal organic cation transporter OCT2 rather than hepatic OCT1. Drug Metab Pharmacokinet 2005;20(5):379-86
   PubMedGoogle Scholar
• Dresser MJ, Xiao G, Leabman MK, Interactions of n-tetraalkylammonium compounds and biguanides with a human renal organic cation transporter (hOCT2). Pharm Res 2002;19(8):1244-7
   PubMed Web of Science ®Google Scholar
• Zhou M, Xia L, Wang J. Metformin transport by a newly cloned proton-stimulated organic cation transporter (plasma membrane monoamine transporter) expressed in human intestine. Drug Metab Dispos 2007;35(10):1956-62
   PubMed Web of Science ®Google Scholar
• Huttunen KM, Mannila A, Laine K, The first bioreversible prodrug of metformin with improved lipophilicity and enhanced intestinal absorption. J Med Chem 2009;52(14):4142-8
   PubMed Web of Science ®Google Scholar
• Linkins LA, Weitz JI. Pharmacology and clinical potential of direct thrombin inhibitors. Curr Pharm Des 2005;11(30):3877-84
   PubMed Web of Science ®Google Scholar
• Cass LM, Efthymiopoulos C, Bye A. Pharmacokinetics of zanamivir after intravenous, oral, inhaled or intranasal administration to healthy volunteers. Clin Pharmacokinet 1999;36(Suppl 1):1-11
   PubMedGoogle Scholar
• He G, Massarella J, Ward P. Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802. Clin Pharmacokinet 1999;37(6):471-84
   PubMed Web of Science ®Google Scholar
• Bloom JD, Gong LI, Baltimore D. Permissive secondary mutations enable the evolution of influenza oseltamivir resistance. Science 2010;328(5983):1272-5
   PubMed Web of Science ®Google Scholar
• Ottmann M, Duchamp MB, Casalegno JS, Novel influenza A(H1N1) 2009 in vitro reassortant viruses with oseltamivir resistance. Antivir Ther 2010;15(5):721-6
   PubMed Web of Science ®Google Scholar
• Li W, Escarpe PA, Eisenberg EJ, Identification of GS 4104 as an orally bioavailable prodrug of the influenza virus neuraminidase inhibitor GS 4071. Antimicrob Agents Chemother 1998;42(3):647-53
   PubMed Web of Science ®Google Scholar
• Young D, Fowler C, Bush K. RWJ-270201 (BCX-1812): a novel neuraminidase inhibitor for influenza. Philos Trans R Soc Lond B Biol Sci 2001;356(1416):1905-13
   PubMed Web of Science ®Google Scholar
• Ettmayer P, Amidon GL, Clement B, Lessons learned from marketed and investigational prodrugs. J Med Chem 2004;47(10):2393-404
   PubMed Web of Science ®Google Scholar
• Hsieh PW, Hung CF, Fang JY. Current prodrug design for drug discovery. Curr Pharm Des 2009;15(19):2236-50
   PubMed Web of Science ®Google Scholar
• Han HK, Amidon GL. Targeted prodrug design to optimize drug delivery. AAPS PharmSci 2000;2(1):E6
   Google Scholar
• Majumdar S, Duvvuri S, Mitra AK. Membrane transporter/receptor-targeted prodrug design: strategies for human and veterinary drug development. Adv Drug Deliv Rev 2004;56(10):1437-52
   PubMed Web of Science ®Google Scholar
• Saulnier MG, Frennesson DB, Deshpande MS, An efficient method for the synthesis of guanidino prodrugs. Bioorg Med Chem Lett 1994;4(16):1985-90
   Web of Science ®Google Scholar
• Humphreys WG, Obermeier MT, Chong S, Oxidative activation of acylguanidine prodrugs: intestinal presystemic activation in rats limits absorption and can be inhibited by co-administration of ketoconazole. Xenobiotica 2003;33(1):93-106
   PubMed Web of Science ®Google Scholar
• Arafa RK, Brun R, Wenzler T, Synthesis, DNA affinity, and antiprotozoal activity of fused ring dicationic compounds and their prodrugs. J Med Chem 2005;48(17):5480-8
   PubMed Web of Science ®Google Scholar
• Maryanoff BE, McComsey DF, Costanzo MJ, Exploration of potential prodrugs of RWJ-445167, an oxyguanidine-based dual inhibitor of thrombin and factor Xa. Chem Biol Drug Des 2006;68(1):29-36
   PubMed Web of Science ®Google Scholar
• Arafa RK, Ismail MA, Munde M, Novel linear triaryl guanidines, N-substituted guanidines and potential prodrugs as antiprotozoal agents. Eur J Med Chem 2008;43(12):2901-8
   PubMed Web of Science ®Google Scholar
• Huttunen KM, Leppanen J, Kemppainen E, Towards metformin prodrugs. Synthesis 2008;(22):3619-24
   Web of Science ®Google Scholar
• Peterlin-Masic L, Cesar J, Zega A. Metabolism-directed optimisation of antithrombotics: the prodrug principle. Curr Pharm Des 2006;12(1):73-91
   PubMed Web of Science ®Google Scholar
• Midgley I, Fitzpatrick K, Taylor LM, Pharmacokinetics and metabolism of the prodrug DB289 (2,5-bis[4-(N-methoxyamidino)phenyl]furan monomaleate) in rat and monkey and its conversion to the antiprotozoal/antifungal drug DB75 (2,5-bis(4-guanylphenyl)furan dihydrochloride). Drug Metab Dispos 2007;35(6):955-67
   PubMed Web of Science ®Google Scholar
• Clement B. Reduction of N-hydroxylated compounds: amidoximes (N-hydroxyamidines) as pro-drugs of amidines. Drug Metab Rev 2002;34(3):565-79
   PubMed Web of Science ®Google Scholar
• Clement B, Mau S, Deters S, Hepatic, extrahepatic, microsomal, and mitochondrial activation of the N-hydroxylated prodrugs benzamidoxime, guanoxabenz, and Ro 48-3656 ([[1-[(2s)-2-[[4-[(hydroxyamino)iminomethyl]benzoyl]amino]-1-oxopropyl]-4- piperidinyl]oxy]-acetic acid). Drug Metab Dispos 2005;33(11):1740-7
   PubMed Web of Science ®Google Scholar
• Brandsch M, Knutter I, Bosse-Doenecke E. Pharmaceutical and pharmacological importance of peptide transporters. J Pharm Pharmacol 2008;60(5):543-85
   PubMed Web of Science ®Google Scholar
• Soul-Lawton J, Seaber E, On N, Absolute bioavailability and metabolic disposition of valaciclovir, the L-valyl ester of acyclovir, following oral administration to humans. Antimicrob Agents Chemother 1995;39(12):2759-64
   PubMed Web of Science ®Google Scholar
• Balimane PV, Tamai I, Guo A, Direct evidence for peptide transporter (PepT1)-mediated uptake of a nonpeptide prodrug, valacyclovir. Biochem Biophys Res Commun 1998;250(2):246-51
   PubMed Web of Science ®Google Scholar
• Sun J, Dahan A, Amidon GL. Enhancing the intestinal absorption of molecules containing the polar guanidino functionality: a double-targeted prodrug approach. J Med Chem 2010;53(2):624-32
   PubMed Web of Science ®Google Scholar
• Sun J, Dahan A, Walls Z, Specificity of a prodrug-activating enzyme hVACVase: the leaving group effect. Mol Pharm 2010;7(6):2362-8
   PubMedGoogle Scholar
• Miller JM, Dahan A, Gupta D, Quasi-equilibrium analysis of the ion-pair mediated membrane transport of low-permeability drugs. J Control Release 2009;137(1):31-7
   PubMed Web of Science ®Google Scholar
• Miller JM, Dahan A, Gupta D, Enabling the intestinal absorption of highly polar antiviral agents: ion-pair facilitated membrane permeation of zanamivir heptyl ester and guanidino oseltamivir. Mol Pharm 2010;7(4):1223-34
   PubMedGoogle Scholar
• Jaimini M, Rana AC, Tanwar YS. Formulation and evaluation of famotidine floating tablets. Curr Drug Deliv 2007;4(1):51-5
   PubMedGoogle Scholar
• Elmowafy EM, Awad GA, Mansour S, Release mechanisms behind polysaccharides-based famotidine controlled release matrix tablets. AAPS PharmSciTech 2008;9(4):1230-9
   PubMed Web of Science ®Google Scholar
• Gupta R, Pathak K. Optimization studies on floating multiparticulate gastroretentive drug delivery system of famotidine. Drug Dev Ind Pharm 2008;34(11):1201-8
   PubMed Web of Science ®Google Scholar
• Ramachandran S, Shaheedha SM, Thirumurugan G, Floating controlled drug delivery system of famotidine loaded hollow microspheres (microballoons) in the stomach. Curr Drug Deliv 2010;7(1):93-7
   PubMedGoogle Scholar
• Guan J, Zhou L, Nie S, A novel gastric-resident osmotic pump tablet: in vitro and in vivo evaluation. Int J Pharm 2010;383(1-2):30-6
   PubMedGoogle Scholar
• Guan J, Zhou L, Pan Y, A novel gastro-retentive osmotic pump capsule using asymmetric membrane technology: in vitro and in vivo evaluation. Pharm Res 2010;27(1):105-14
   PubMed Web of Science ®Google Scholar
• Pentikainen PJ. Bioavailability of metformin. Comparison of solution, rapidly dissolving tablet, and three sustained release products. Int J Clin Pharmacol Ther Toxicol 1986;24(4):213-20
   PubMedGoogle Scholar
• Stepensky D, Friedman M, Srour W, Preclinical evaluation of pharmacokinetic-pharmacodynamic rationale for oral CR metformin formulation. J Control Release 2001;71(1):107-15
   PubMed Web of Science ®Google Scholar
• Gusler G, Gorsline J, Levy G, Pharmacokinetics of metformin gastric-retentive tablets in healthy volunteers. J Clin Pharmacol 2001;41(6):655-61
   PubMed Web of Science ®Google Scholar
• Di Colo G, Falchi S, Zambito Y. In vitro evaluation of a system for pH-controlled peroral delivery of metformin. J Control Release 2002;80(1-3):119-28
   PubMed Web of Science ®Google Scholar
• Timmins P, Donahue S, Meeker J, Steady-state pharmacokinetics of a novel extended-release metformin formulation. Clin Pharmacokinet 2005;44(7):721-9
   PubMed Web of Science ®Google Scholar
• Di Colo G, Zambito Y, Baggiani A, A site-specific controlled-release system for metformin. J Pharm Pharmacol 2005;57(5):565-71
   PubMed Web of Science ®Google Scholar
• Li J, Jin Y, Wang TY, Relative bioavailability and bioequivalence of metforphin hydrochloride extended-released and immediate-released tablets in healthy Chinese volunteers. Eur J Drug Metab Pharmacokinet 2007;32(1):21-8
   PubMed Web of Science ®Google Scholar
• Kreuter J. Nanoparticles and microparticles for drug and vaccine delivery. J Anat 1996;189(Pt 3):503-5
   PubMed Web of Science ®Google Scholar
• Florence AT, Hussain N. Transcytosis of nanoparticle and dendrimer delivery systems: evolving vistas. Adv Drug Deliv Rev 2001;50(Suppl 1):S69-89
   Google Scholar
• Lu JM, Wang X, Marin-Muller C, Current advances in research and clinical applications of PLGA-based nanotechnology. Expert Rev Mol Diagn 2009;9(4):325-41
   PubMed Web of Science ®Google Scholar
• Pandey R, Khuller GK. Nanoparticle-based oral drug delivery system for an injectable antibiotic – streptomycin. Evaluation in a murine tuberculosis model. Chemotherapy 2007;53(6):437-41
   PubMed Web of Science ®Google Scholar
• Bowman K, Leong KW. Chitosan nanoparticles for oral drug and gene delivery. Int J Nanomed 2006;1(2):117-28
   PubMed Web of Science ®Google Scholar
• Lu E, Franzblau S, Onyuksel H, Preparation of aminoglycoside-loaded chitosan nanoparticles using dextran sulphate as a counterion. J Microencapsul 2009;26(4):346-54
   PubMed Web of Science ®Google Scholar